Clinical Trial Update: A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial comparing diclofenac sodium 3% gel to Solaraze 3% gel for actinic keratosis on the face or bald scalp has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Diclofenac Sodium Gel 3% (diclofenac sodium gel 3%)
• Solaraze Gel 3% (diclofenac sodium)

Snippet

Sponsor: Teva Pharmaceuticals USA | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED